Skip to Main Content

Paper Details

A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
J Thorac Oncol
41
2021
DLL3, ES, ES SCLC, Extensive-Stage SCLC, Ipilimumab, Patients, Rova, Rovalpituzumab, Rovalpituzumab Tesirine, Solid Tumors, acute kidney injury, anemia, extensive-stage SCLC, ipilimumab, nivolumab, patients, pleural effusion, pneumonitis, rovalpituzumab, rovalpituzumab tesirine
Author NameAffiliation
Jyoti MalhotraRutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Daniel MorgenszternWashington University School of Medicine
Giuseppe CuriglianoIstituto Europeo di Oncologia, IRCCS, University of Milano
David MaagAbbVie Inc.
  • 1 - 4

Datasets

Release 1.2